Primates in Medical Research
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
EAZA Best Practice Guidelines Bonobo (Pan Paniscus)
EAZA Best Practice Guidelines Bonobo (Pan paniscus) Editors: Dr Jeroen Stevens Contact information: Royal Zoological Society of Antwerp – K. Astridplein 26 – B 2018 Antwerp, Belgium Email: [email protected] Name of TAG: Great Ape TAG TAG Chair: Dr. María Teresa Abelló Poveda – Barcelona Zoo [email protected] Edition: First edition - 2020 1 2 EAZA Best Practice Guidelines disclaimer Copyright (February 2020) by EAZA Executive Office, Amsterdam. All rights reserved. No part of this publication may be reproduced in hard copy, machine-readable or other forms without advance written permission from the European Association of Zoos and Aquaria (EAZA). Members of the European Association of Zoos and Aquaria (EAZA) may copy this information for their own use as needed. The information contained in these EAZA Best Practice Guidelines has been obtained from numerous sources believed to be reliable. EAZA and the EAZA APE TAG make a diligent effort to provide a complete and accurate representation of the data in its reports, publications, and services. However, EAZA does not guarantee the accuracy, adequacy, or completeness of any information. EAZA disclaims all liability for errors or omissions that may exist and shall not be liable for any incidental, consequential, or other damages (whether resulting from negligence or otherwise) including, without limitation, exemplary damages or lost profits arising out of or in connection with the use of this publication. Because the technical information provided in the EAZA Best Practice Guidelines can easily be misread or misinterpreted unless properly analysed, EAZA strongly recommends that users of this information consult with the editors in all matters related to data analysis and interpretation. -
Evolution of Clinical Trials Throughout History
Evolution of clinical trials throughout history Emma M. Nellhaus1, Todd H. Davies, PhD1 Author Affiliations: 1. Office of Research and Graduate Education, Marshall University Joan C. Edwards School of Medicine, Huntington, West Virginia The authors have no financial disclosures to declare and no conflicts of interest to report. Corresponding Author: Todd H. Davies, PhD Director of Research Development and Translation Marshall University Joan C. Edwards School of Medicine Huntington, West Virginia Email: [email protected] Abstract The history of clinical research accounts for the high ethical, scientific, and regulatory standards represented in current practice. In this review, we aim to describe the advances that grew from failures and provide a comprehensive view of how the current gold standard of clinical practice was born. This discussion of the evolution of clinical trials considers the length of time and efforts that were made in order to designate the primary objective, which is providing improved care for our patients. A gradual, historic progression of scientific methods such as comparison of interventions, randomization, blinding, and placebos in clinical trials demonstrates how these techniques are collectively responsible for a continuous advancement of clinical care. Developments over the years have been ethical as well as clinical. The Belmont Report, which many investigators lack appreciation for due to time constraints, represents the pinnacle of ethical standards and was developed due to significant misconduct. Understanding the history of clinical research may help investigators value the responsibility of conducting human subjects’ research. Keywords Clinical Trials, Clinical Research, History, Belmont Report In modern medicine, the clinical trial is the gold standard and most dominant form of clinical research. -
The Survival of the Central American Squirrel Monkey
SIT Graduate Institute/SIT Study Abroad SIT Digital Collections Independent Study Project (ISP) Collection SIT Study Abroad Fall 2005 The urS vival of the Central American Squirrel monkey (Saimiri oerstedi): the habitat and behavior of a troop on the Burica Peninsula in a conservation context Liana Burghardt SIT Study Abroad Follow this and additional works at: https://digitalcollections.sit.edu/isp_collection Part of the Animal Sciences Commons, and the Environmental Sciences Commons Recommended Citation Burghardt, Liana, "The urS vival of the Central American Squirrel monkey (Saimiri oerstedi): the habitat and behavior of a troop on the Burica Peninsula in a conservation context" (2005). Independent Study Project (ISP) Collection. 435. https://digitalcollections.sit.edu/isp_collection/435 This Unpublished Paper is brought to you for free and open access by the SIT Study Abroad at SIT Digital Collections. It has been accepted for inclusion in Independent Study Project (ISP) Collection by an authorized administrator of SIT Digital Collections. For more information, please contact [email protected]. The Survival of the Central American Squirrel monkey (Saimiri oerstedi): the habitat and behavior of a troop on the Burica Peninsula in a conservation context Liana Burghardt Carleton College Fall 2005 Burghardt 2 I dedicate this paper which documents my first scientific adventure in the field to my father. “It is often necessary to put aside the objective measurements favored in controlled laboratory environments and to adopt a more subjective naturalistic viewpoint in order to see pattern and consistency in the rich, varied context of the natural environment” (Baldwin and Baldwin 1971: 48). Acknowledgments This paper has truly been an adventure and as is common I have many people I wish to thank. -
U.S. Investments in Medical and Health Research and Development 2013 - 2017 Advocacy Has Helped Bring About Five Years of Much-Needed Growth in U.S
Fall 2018 U.S. Investments in Medical and Health Research and Development 2013 - 2017 Advocacy has helped bring about five years of much-needed growth in U.S. medical and health research investment. More advocacy is critical now to ensure our nation steps up in response to health threats that we can—we must—overcome. More Than Half Favor Doubling Federal Spending on Medical Research Do you favor or oppose doubling federal spending on medical research over the next five years? 19% Not Sure 23% 8% Strongly favor Strongly oppose 16% 35% Somewhat oppose Somewhat favor Source: A Research!America survey of U.S. adults conducted in partnership with Zogby Analytics in January 2018. Research!America 3 Introduction Investment1 in medical and health research and development (R&D) in the U.S. grew by $38.8 billion or 27% from 2013 to 2017. Industry continues to invest more than any other sector, accounting for 67% of total spending in 2017, followed by the federal government at 22%. Federal investments increased from 2016 to 2017, the second year of growth after a dip from 2014 to 2015. Overall, federal investment increased by $6.1 billion or 18.4% from 2013 to 2017, but growth has been uneven across federal health agencies. Investment by other sectors, including academic and research institutions, foundations, state and local governments, and voluntary health associations and professional societies, also increased from 2013 to 2017. Looking ahead, medical and health R&D spending is expected to move in an upward trajectory in 2018 but will continue to fall short relative to the health and economic impact of major health threats. -
Proposal for Inclusion of the Chimpanzee
CMS Distribution: General CONVENTION ON MIGRATORY UNEP/CMS/COP12/Doc.25.1.1 25 May 2017 SPECIES Original: English 12th MEETING OF THE CONFERENCE OF THE PARTIES Manila, Philippines, 23 - 28 October 2017 Agenda Item 25.1 PROPOSAL FOR THE INCLUSION OF THE CHIMPANZEE (Pan troglodytes) ON APPENDIX I AND II OF THE CONVENTION Summary: The Governments of Congo and the United Republic of Tanzania have jointly submitted the attached proposal* for the inclusion of the Chimpanzee (Pan troglodytes) on Appendix I and II of CMS. *The geographical designations employed in this document do not imply the expression of any opinion whatsoever on the part of the CMS Secretariat (or the United Nations Environment Programme) concerning the legal status of any country, territory, or area, or concerning the delimitation of its frontiers or boundaries. The responsibility for the contents of the document rests exclusively with its author. UNEP/CMS/COP12/Doc.25.1.1 PROPOSAL FOR THE INCLUSION OF CHIMPANZEE (Pan troglodytes) ON APPENDICES I AND II OF THE CONVENTION ON THE CONSERVATION OF MIGRATORY SPECIES OF WILD ANIMALS A: PROPOSAL Inclusion of Pan troglodytes in Appendix I and II of the Convention on the Conservation of Migratory Species of Wild Animals. B: PROPONENTS: Congo and the United Republic of Tanzania C: SUPPORTING STATEMENT 1. Taxonomy 1.1 Class: Mammalia 1.2 Order: Primates 1.3 Family: Hominidae 1.4 Genus, species or subspecies, including author and year: Pan troglodytes (Blumenbach 1775) (Wilson & Reeder 2005) [Note: Pan troglodytes is understood in the sense of Wilson and Reeder (2005), the current reference for terrestrial mammals used by CMS). -
Clinical Research Services
Clinical Research Services Conducting efficient, innovative clinical research from initial planning to closeout WHY LEIDOS LIFE SCIENCES? In addition to developing large-scale technology programs for U.S. federal f Leidos has expertise agencies with a focus on health, Leidos provides a broad range of clinical supporting all product services and solutions to researchers, product sponsors, U.S. government development phases agencies, and other biomedical enterprises, hospitals, and health systems. for vaccines, drugs, and Our broad research experience enables us to support programs throughout biotherapeutics the development life cycle: from concept through the exploratory, f Leidos understands the development, pre-clinical, and clinical phases, as well as with product need to control clinical manufacturing and launching. Leidos designs and develops customized project scope, timelines, solutions that support groundbreaking medical research, optimize business and cost while remaining operations, and expedite the discovery of safe and effective medical flexible amidst shifting products. We apply our technical knowledge and experience in selecting research requirements institutions, clinical research organizations, and independent research f Leidos remains vendor- facilities to meet the specific needs of each clinical study. We also manage neutral while fostering and team integration, communication, and contracts throughout the project. managing collaborations Finally, Leidos has a proven track record of ensuring that research involving with -
Goeldi's Monkey
Goeldi’s Monkey (Callimico) Callimico goeldii Class: Mammalia Order: Primates Family: Callitrichidae Characteristics: Goeldi’s monkeys are very small primates. They are approximately the size of a squirrel. These monkeys are very dark in color, ranging in shades of black and brown. They have a mane-like appearance with longer fur near the head and neck. The Goeldi’s monkeys have claws on all of their digits except the second. These small primates weigh only 22oz on average. They have a body length that is in the range of 8-12 inches. The non-prehensile tail is usually longer than the body. (Primate Info Net) Behavior: The Goeldi’s monkey lives in small family groups usually consisting of a breeding pair and other family members. These groups will Range & Habitat: Upper Amazonian rainforests of grow up to 10 individuals in size. They are very social animals and will southern Colombia, eastern spend a great deal of time grooming and communicating with Ecuador and Peru, western Brazil, vocalizations, scent, facial, and body language. (Animal Diversity) This and northern Bolivia. monkey forages in the understory of the forest and rarely goes up into the canopy. They are very agile and can leap up to 13 feet between branches! (Arkive) Reproduction: In the wild, mating occurs during the wet season of September through November. Females have a gestation of 145-152 days. The female will give birth to a single young twice a year. The mother will care for the newborn for 10-20 days, then the rest of the family group will assist the mother. -
Adaptive Designs in Clinical Trials: Why Use Them, and How to Run and Report Them Philip Pallmann1* , Alun W
Pallmann et al. BMC Medicine (2018) 16:29 https://doi.org/10.1186/s12916-018-1017-7 CORRESPONDENCE Open Access Adaptive designs in clinical trials: why use them, and how to run and report them Philip Pallmann1* , Alun W. Bedding2, Babak Choodari-Oskooei3, Munyaradzi Dimairo4,LauraFlight5, Lisa V. Hampson1,6, Jane Holmes7, Adrian P. Mander8, Lang’o Odondi7, Matthew R. Sydes3,SofíaS.Villar8, James M. S. Wason8,9, Christopher J. Weir10, Graham M. Wheeler8,11, Christina Yap12 and Thomas Jaki1 Abstract Adaptive designs can make clinical trials more flexible by utilising results accumulating in the trial to modify the trial’s course in accordance with pre-specified rules. Trials with an adaptive design are often more efficient, informative and ethical than trials with a traditional fixed design since they often make better use of resources such as time and money, and might require fewer participants. Adaptive designs can be applied across all phases of clinical research, from early-phase dose escalation to confirmatory trials. The pace of the uptake of adaptive designs in clinical research, however, has remained well behind that of the statistical literature introducing new methods and highlighting their potential advantages. We speculate that one factor contributing to this is that the full range of adaptations available to trial designs, as well as their goals, advantages and limitations, remains unfamiliar to many parts of the clinical community. Additionally, the term adaptive design has been misleadingly used as an all-encompassing label to refer to certain methods that could be deemed controversial or that have been inadequately implemented. We believe that even if the planning and analysis of a trial is undertaken by an expert statistician, it is essential that the investigators understand the implications of using an adaptive design, for example, what the practical challenges are, what can (and cannot) be inferred from the results of such a trial, and how to report and communicate the results. -
Good Statistical Practices for Contemporary Meta-Analysis: Examples Based on a Systematic Review on COVID-19 in Pregnancy
Review Good Statistical Practices for Contemporary Meta-Analysis: Examples Based on a Systematic Review on COVID-19 in Pregnancy Yuxi Zhao and Lifeng Lin * Department of Statistics, Florida State University, Tallahassee, FL 32306, USA; [email protected] * Correspondence: [email protected] Abstract: Systematic reviews and meta-analyses have been increasingly used to pool research find- ings from multiple studies in medical sciences. The reliability of the synthesized evidence depends highly on the methodological quality of a systematic review and meta-analysis. In recent years, several tools have been developed to guide the reporting and evidence appraisal of systematic reviews and meta-analyses, and much statistical effort has been paid to improve their methodological quality. Nevertheless, many contemporary meta-analyses continue to employ conventional statis- tical methods, which may be suboptimal compared with several alternative methods available in the evidence synthesis literature. Based on a recent systematic review on COVID-19 in pregnancy, this article provides an overview of select good practices for performing meta-analyses from sta- tistical perspectives. Specifically, we suggest meta-analysts (1) providing sufficient information of included studies, (2) providing information for reproducibility of meta-analyses, (3) using appro- priate terminologies, (4) double-checking presented results, (5) considering alternative estimators of between-study variance, (6) considering alternative confidence intervals, (7) reporting predic- Citation: Zhao, Y.; Lin, L. Good tion intervals, (8) assessing small-study effects whenever possible, and (9) considering one-stage Statistical Practices for Contemporary methods. We use worked examples to illustrate these good practices. Relevant statistical code Meta-Analysis: Examples Based on a is also provided. -
Short List of Commonly Used Acronyms in Clinical Research
Short List of Commonly Used Acronyms in Clinical Research ACRP Association of Clinical Research Professionals AE Adverse Event ADR Adverse Drug Reaction AMA American Medical Association BAA Business Associate Agreement BIND Biological IND CA Coverage Analysis CAP College of American Pathologists CBCTN Community Based Clinical Trials Network CCRA Certified Clinical Research Associate (ACRP) CCRC Certified Clinical Research Coordinator (ACRP) CCRT Center for Clinical Research & Technology CCRP Certified Clinical Research Professional (SoCRA) CDA Confidential Disclosure Agreement CDC Center for Disease Control CFR Code of Federal Regulations CIRBI Center for IRB Intelligence CITI Collaborative Institutional Training Initiative CLIA Clinical Laboratory Improvement Amendments CME Continuing Medical Education CMS Central Management System COI Conflict of Interest CRA Clinical Research Associate CRC Clinical Research Coordinator CREC Continuing Research Education Credit CRF Case Report Form CRO Clinical Research Organization CTA Clinical Trial Agreement CTSC Clinical & Translational Science Collaborative CV Curriculum Vitae DCF Data Correction Form / Data Clarification Form DEA Drug Enforcement Agency (law enforcement division of FDA) DHHS Department of Health and Human Services DOS Date of Service DSMB or Data and Safety Monitoring Board (Plan or Committee) DSMP/C EAB Ethical Advisory Board (similar to IRB, used by other nations) EDC Electronic Data Capture FDA Food and Drug Administration FDA-482 Notice of Inspection FDA-483 Notice of Adverse -
8. Primate Evolution
8. Primate Evolution Jonathan M. G. Perry, Ph.D., The Johns Hopkins University School of Medicine Stephanie L. Canington, B.A., The Johns Hopkins University School of Medicine Learning Objectives • Understand the major trends in primate evolution from the origin of primates to the origin of our own species • Learn about primate adaptations and how they characterize major primate groups • Discuss the kinds of evidence that anthropologists use to find out how extinct primates are related to each other and to living primates • Recognize how the changing geography and climate of Earth have influenced where and when primates have thrived or gone extinct The first fifty million years of primate evolution was a series of adaptive radiations leading to the diversification of the earliest lemurs, monkeys, and apes. The primate story begins in the canopy and understory of conifer-dominated forests, with our small, furtive ancestors subsisting at night, beneath the notice of day-active dinosaurs. From the archaic plesiadapiforms (archaic primates) to the earliest groups of true primates (euprimates), the origin of our own order is characterized by the struggle for new food sources and microhabitats in the arboreal setting. Climate change forced major extinctions as the northern continents became increasingly dry, cold, and seasonal and as tropical rainforests gave way to deciduous forests, woodlands, and eventually grasslands. Lemurs, lorises, and tarsiers—once diverse groups containing many species—became rare, except for lemurs in Madagascar where there were no anthropoid competitors and perhaps few predators. Meanwhile, anthropoids (monkeys and apes) emerged in the Old World, then dispersed across parts of the northern hemisphere, Africa, and ultimately South America. -
A Framework to Assess Empirical Reproducibility in Biomedical Research Leslie D
McIntosh et al. BMC Medical Research Methodology (2017) 17:143 DOI 10.1186/s12874-017-0377-6 RESEARCH ARTICLE Open Access Repeat: a framework to assess empirical reproducibility in biomedical research Leslie D. McIntosh1, Anthony Juehne1*, Cynthia R. H. Vitale2, Xiaoyan Liu1, Rosalia Alcoser1, J. Christian Lukas1 and Bradley Evanoff3 Abstract Background: The reproducibility of research is essential to rigorous science, yet significant concerns of the reliability and verifiability of biomedical research have been recently highlighted. Ongoing efforts across several domains of science and policy are working to clarify the fundamental characteristics of reproducibility and to enhance the transparency and accessibility of research. Methods: The aim of the proceeding work is to develop an assessment tool operationalizing key concepts of research transparency in the biomedical domain, specifically for secondary biomedical data research using electronic health record data. The tool (RepeAT) was developed through a multi-phase process that involved coding and extracting recommendations and practices for improving reproducibility from publications and reports across the biomedical and statistical sciences, field testing the instrument, and refining variables. Results: RepeAT includes 119 unique variables grouped into five categories (research design and aim, database and data collection methods, data mining and data cleaning, data analysis, data sharing and documentation). Preliminary results in manually processing 40 scientific manuscripts indicate components of the proposed framework with strong inter-rater reliability, as well as directions for further research and refinement of RepeAT. Conclusions: The use of RepeAT may allow the biomedical community to have a better understanding of the current practices of research transparency and accessibility among principal investigators.